Published in Rambam Maimonides Med J on July 30, 2015
Preventing ESRD in Overt Nephropathy of Type 2 Diabetes (VALID) | NCT00494715
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med (2004) 49.19
Prediction of coronary heart disease using risk factor categories. Circulation (1998) 48.81
Global burden of hypertension: analysis of worldwide data. Lancet (2005) 32.76
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med (2000) 29.25
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med (2001) 22.32
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care (2012) 21.62
Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med (2010) 21.49
Standards of medical care in diabetes--2014. Diabetes Care (2014) 20.97
Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med (2008) 19.76
A potential decline in life expectancy in the United States in the 21st century. N Engl J Med (2005) 19.63
Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet (2010) 18.36
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med (1993) 18.15
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med (2001) 17.24
Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet (2005) 17.08
Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med (2007) 16.95
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med (1991) 16.19
Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract (1995) 12.51
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA (2002) 12.29
Factors of risk in the development of coronary heart disease--six year follow-up experience. The Framingham Study. Ann Intern Med (1961) 12.08
Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol (2004) 11.23
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med (2001) 10.36
The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health (2009) 9.79
Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med (2012) 9.46
The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int (2010) 9.25
Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet (2010) 9.20
Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med (2008) 9.19
The epidemiology of obesity. Gastroenterology (2007) 8.35
The burden and costs of chronic diseases in low-income and middle-income countries. Lancet (2007) 8.33
Relation between kidney function, proteinuria, and adverse outcomes. JAMA (2010) 8.26
Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol (2004) 8.21
Retracted Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet (2003) 7.69
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet (2010) 7.69
Body mass index and risk for end-stage renal disease. Ann Intern Med (2006) 7.56
Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: third National Health and Nutrition Examination Survey, 1988-1994. Am J Clin Nutr (2002) 7.34
Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med (2013) 7.29
Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest (2009) 7.09
Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int (2006) 7.02
Trans fatty acids and cardiovascular disease. N Engl J Med (2006) 6.67
Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol (2004) 6.59
Preventing microalbuminuria in type 2 diabetes. N Engl J Med (2004) 6.41
Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med (2003) 6.41
Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int (2007) 6.35
Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med (2007) 6.29
Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet (2009) 6.25
Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med (2001) 6.22
Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med (2004) 6.21
Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med (2014) 5.93
Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol (2005) 5.76
Strict blood-pressure control and progression of renal failure in children. N Engl J Med (2009) 5.71
Blood pressure and end-stage renal disease in men. N Engl J Med (1996) 5.68
New loci associated with kidney function and chronic kidney disease. Nat Genet (2010) 5.58
Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med (1995) 5.50
Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med (2003) 5.47
The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med (2004) 5.45
The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med (2005) 5.45
Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med (1984) 5.35
Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation (2005) 5.29
Dialysis-requiring acute renal failure increases the risk of progressive chronic kidney disease. Kidney Int (2009) 5.28
Shattuck lecture--cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med (1997) 5.25
Prolonged survival of human-kidney homografts by immunosuppressive drug therapy. N Engl J Med (1963) 5.14
Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA (2010) 5.06
Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med (2008) 4.98
Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation (2009) 4.87
A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. Arch Intern Med (2009) 4.80
Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol (1981) 4.75
Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol (2007) 4.59
Association of kidney function and albuminuria with cardiovascular mortality in older vs younger individuals: The HUNT II Study. Arch Intern Med (2007) 4.58
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int (2004) 4.51
Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med (1974) 4.23
Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med (2007) 4.23
Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med (2014) 4.13
Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med (2009) 4.05
Sugar-sweetened beverages, serum uric acid, and blood pressure in adolescents. J Pediatr (2009) 4.04
Obesity-related glomerulopathy: an emerging epidemic. Kidney Int (2001) 3.98
US Renal Data System 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis (2015) 3.94
Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group. JAMA (1992) 3.86
Proteinuria and the risk of developing end-stage renal disease. Kidney Int (2003) 3.73
Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries. J Hypertens (2009) 3.70
Obesity and risk for chronic renal failure. J Am Soc Nephrol (2006) 3.67
Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med (2012) 3.62
Metabolic effects of fructose and the worldwide increase in obesity. Physiol Rev (2010) 3.60
A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA (1982) 3.54
Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet (2005) 3.52
Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet (2006) 3.43
Food reward in the absence of taste receptor signaling. Neuron (2008) 3.37
Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis (2000) 3.37
Targeted inactivation of Npt2 in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities. Proc Natl Acad Sci U S A (1998) 3.24
Early recognition and prevention of chronic kidney disease. Lancet (2010) 3.19
Progression, remission, regression of chronic renal diseases. Lancet (2001) 3.17
Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int (2002) 3.10
High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant (2009) 3.08
Insulin signaling to the glomerular podocyte is critical for normal kidney function. Cell Metab (2010) 3.05
Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension (2008) 2.99
Impact of activated vitamin D and race on survival among hemodialysis patients. J Am Soc Nephrol (2008) 2.96
Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest (1986) 2.96
How fibroblast growth factor 23 works. J Am Soc Nephrol (2007) 2.92
High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant (2007) 2.91
Effect of Jewish-Arab Ancestry and Gender Matching on Clinical Outcome of Lung Transplantation in Israel. Isr Med Assoc J (2016) 0.75